neuroClues Raises €10M Series A to Scale AI-Powered Neurological Biomarkers Across Europe
Summary
neuroClues has raised a €10 million Series A to accelerate one of the fastest clinical rollouts in European neurotech, bringing total capital raised to €25 million. The round was led by Teampact Ventures, White Fund, and the EIC Fund with participation from existing investors. The company has developed a portable, CE-marked Class IIa medical device that extracts neurological biomarkers from eye movements in minutes using high-speed infrared imaging and proprietary AI algorithms. The device is deployed across seven European countries and aims to replace the subjective follow-my-finger test with quantified, reproducible data.
Why it matters
neuroClues addresses a critical diagnostic gap where one in five Parkinson's disease patients is still misdiagnosed and by the time correct identification occurs, 65% of affected neurons are already lost. By turning a century of oculomotor research into a practical clinical tool, neuroClues could enable earlier detection of neurodegenerative diseases when interventions are most effective. The rapid clinical adoption across seven countries within months of CE certification demonstrates strong product-market fit and unmet clinical need.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial